On September 19, 2019, the first post-marketing implantation of the VitaFlow^® Valve System and Alwide^® Balloon in Lingnan Region was successfully performed by the team of Prof. Luo Jianfang at Guangdong General Hospital.

The implantation was performed in an 84-year-old male patient with severe tricuspid valve calcification and severe femoral artery stenosis. Through peripheral balloon dilatation, the artery reached the ideal diameter, enabling the sheath to be inserted smoothly. After the implantation of the VitaFlow^® valve, the ultrasonic assessment showed no Perivalvular Leak (PVL), no regurgitation, and no pressure gradient.

Director Luo Jianfang highly appraised the VitaFlow^® Valve System after the surgery, “The VitaFlow^® Valve System performed well in today’s surgery. As domestic first self-expanding bovine pericardial bioprosthesis approved for marketing, its innovative design of double-layer skirt has effectively reduced the occurrence of postsurgical PVL. Its mixed density nitinol frame enables the valve to effectively unfold the leaflets. The globally innovative motorized delivery system has also improved the stability and accuracy of valve release during surgery.” Meanwhile, Director Luo Jianfang also spoke highly of the Alwide^® Balloon, “As a non-compliant balloon specially used for valve dilation, Alwide^® has a unique advantage for severe calcification and dilation accuracy.”